'Clarification that (CE Certification) for (Pancreatic Cancer Indication)
Should be granted by (BSI) after the (Stage-1, 20 Patient Safety Assessment) is completed'
That is not a given that data will be good. What is the plan B if the data from the first 20 is not clear cut?
And as for the data being available in September, I think this is most uncertain. They only have ethics for one centre, it could take to September to get ethics for the other centres. I would think September 2018 would be more realistc.
So the positives are :-
'2) Possible less dilution,
Due to (19,000,000 Options @ 5 cents) (Expiring 3/06/2017)
Held by (Martin Rogers) who resigned in 2016, possibly not being exercised'
Well that would mean the shares falling to less than 5c by end of June. Difficult to see that as a+ve event for most SH?
OSL Price at posting:
9.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)